A Promising Oral GLP-1 Drug for Type 2 Diabetes and Obesity
Once a-day, daily oral dose of a novel small-molecule GLP-1 receptor agonist, AZD5004, has demonstrated promising potential for the treatment of type 2 diabetes and obesity. In a Phase I first-in-human study, the drug showed potent GLP-1 receptor activation, enhanced glucose-dependent insulin secretion, and dose-dependent reductions in blood glucose and body weight. Preclinical studies also revealed significant long-term weight-management benefits and a favourable safety profile. Importantly, no serious adverse events were reported in clinical testing, supporting the continued development of AZD5004 as a convenient and effective oral metabolic therapy.
A Promising Oral GLP-1 Drug for Type 2 Diabetes and Obesity Read More »










